"IGC-AD1 relies on low-doses of THC, a psychoactive cannabinoid, and another compound as active agents in trials for Alzheimer’s. The formulation has recently completed phase 1 of clinical trials required by the FDA and demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating a key protein that is responsible for Aβ plaques; a key hallmark of the disease."
India Globalization Capital, Inc. (AMEX:IGC) has begun “A phase 2, multi-center, double-blind, randomized, placebo-controlled, trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease”.
“The findings suggest that medical marijuana legalization may have been associated with lower use of opioids by some adult patients receiving cancer treatment”
State-level medical marijuana legalization is associated with a significant decrease in opioid prescriptions and use among certain cancer patients, according to a new study from the American Medical Association. The study, which analyzed data on insurance claims from 38,189 people with recently diag...
"A team of investigators affiliated with Harvard Medical School assessed the safety and efficacy of CBD extracts in a cohort of anxiety patients over a four-week period. Trial participants consumed oral extracts three times daily. Extracts contained approximately 10mgs of CBD and less than one percent THC. Subjects in the trial had either no prior experience with cannabis products or had been abstinent from cannabis for at least one year.
Researchers reported significant improvements in patients’ symptoms over the course of the trial. “Treatment response analyses revealed rapid onset of clinically significant reductions in anxiety with most patients achieving and maintaining treatment response after one week and all patients achieving and maintaining treatment response by week three,” they determined. “Secondary outcome assessments demonstrated improvements on measures of mood, sleep disturbance, quality of life and executive functioning following treatment. … Specifically, patients exhibited significantly faster performance with fewer errors on several tasks of executive function relative to baseline, while assessments of visual and verbal memory remained stable. These findings are consistent with data from observational investigations reporting long-term treatment with medical cannabis is associated with improved clinical state and executive functioning.”
Authors reported that CBD doses were “well-tolerated with no serious adverse events and few side effects.”
“Patients exhibited significantly faster performance with fewer errors on several tasks of executive function relative to baseline,” investigators concluded.